Multifaceted Role of Extracellular Vesicles: Intercellular Messengers to Therapeutic Applications: A Narrative Review Authors: Kajal Kamra, Satya Kumar Lalam, Shefali Srivastava, Madan Kumar Arumugam, Lokesh Kumar Boopathy, Simran Takkar, Zhiqiu Xia, Sabarinath Peruvemba Subramanian Published: 2026 ABSTRACT ABSTRACTBackground and AimsExtracellular vesicles (EVs) are nanoscale carriers, including exosomes, microvesicles, and apoptotic bodies, that mediate intercellular communication by transporting proteins, nucleic acids, lipids, and metabolites. They regulate immunity, tissue repair, and cell differentiation. Increasing evidence highlights their dual roles in disease, where they may promote tumor growth and immune evasion but also serve as diagnostic and therapeutic tools. This review synthesizes advances in EV biology, their roles in health and disease, and their therapeutic potential.MethodsWe conducted a narrative review of recent literature, focusing on EV isolation methods, biological functions, and clinical applications. Sources were selected to capture both mechanistic insights and translational perspectives.ResultsAdvances in isolation technologies, from ultracentrifugation to microfluidics, have improved the precision of EV characterization. EVs exhibit distinct molecular signatures, positioning them as promising biomarkers in cancer, cardiovascular, neurodegenerative, autoimmune, and infectious diseases. Mechanistic studies demonstrate their roles in immune modulation, tissue remodeling, and regeneration. As therapeutic agents, EVs show promise as drug delivery systems and as platforms for gene and immunotherapies, offering enhanced targeting and reduced toxicity compared to synthetic nanoparticles. Engineered EVs and hybrid EV–liposome systems further expand their applications, though challenges persist in scalability, standardization, and safety.ConclusionEVs are central mediators of intercellular communication with transformative potential in diagnostics and therapeutics. Their biological properties position them as valuable biomarkers and delivery vehicles in precision medicine. Overcoming translational challenges, such as immunogenicity, oncogenic risks, and manufacturing limitations, will be essential for their successful clinical integration.Keywords: biomarker, disease pathogenesis, extracellular vesicles, intercellular communication, therapeutic applications Abbreviations asymmetric flow field‐flow fractionation arrestin domain‐containing protein 1 blood–brain barrier cancer‐associated fibroblast cushioned ultracentrifugation dielectrophores density gradient ultracentrifugation dynamic light scattering differential ultracentrifugation extracellular matrix endosomal sorting complex required for transport extracellular vesicle fluorescence‐activated cell sorting field‐flow fractionation hepatocellular carcinoma hypoxia‐inducible factor‐1α ischemia–reperfusion mesenchymal stem cell multivesicular bodies natural killer nanoparticle tracking analysis pannexin 1 channel Rho‐associated coiled‐coil‐containing protein kinases 1 size exclusion chromatography transmission electron microscopy tumor microenvironment T‐regulatory cell vascular endothelial growth factor Introduction to Extracellular Vesicles (EVs) EVs are lipid bilayer‐bound vesicles measuring between 30 nm and 5 µm (or 5000 nm), released by cells into the extracellular environment. Initially, EVs were considered unwanted cellular debris, and early research primarily focused on their physical attributes like size and morphology [1]. However, EVs are now recognized as vital mediators of intercellular communication involved in various biological processes and disease progression. The biogenesis of EVs includes fundamental intracellular trafficking processes that determine cargo selection and facilitate exocytosis during their release [2]. Different types of EVs have distinct biogenesis mechanisms, resulting in unique characteristics such as size, density, surface proteins, and cargo composition, which are used to classify them into subtypes. The main subtypes include exosomes, microvesicles, and apoptotic bodies (Figure 1). Schematic presentation illustrating the main subtypes of extracellular vesicles (EV). EVs are generated through multiple distinct pathways. (1) Exosome biogenesis: Exosomes form when early endosomes mature into multivesicular bodies (MVBs), which generate intraluminal vesicles (ILVs) through inward budding of the endosomal membrane. MVBs either fuse with the plasma membrane to release ILVs as exosomes or with lysosomes for degradation. (2) Microvesicle biogenesis: Microvesicles are produced by the outward budding and fission of the plasma membrane. (3) Apoptotic body biogenesis: Apoptotic bodies are released during programmed cell death through membrane blebbing. Types of EVs Exosomes (30–150 nm) are formed through the inward budding of endosomal compartments, leading to the creation of multivesicular bodies (MVBs) via sequential invagination of the endosomal membrane. When MVBs fuse with the plasma membrane, exosomes are released into the extracellular space [3, 4, 5, 6]. Microvesicles (50–1000 nm), also called ectosomes, are produced by the direct outward budding of the plasma membrane [7]. Apoptotic bodies (1–5 μm or 1000–5000 nm) arise from the fragmentation of cells during programmed cell death [8, 9], however, studies have reported that apoptotic bodies can reach sizes up to 10 μm, particularly those derived from human Jurkat T cells, LIM1215 colon carcinoma cells, and THP‐1 monocytic cells, depending on the characteristics of the parental cells and the biogenesis mechanism [10]. Exosomes are made up of a phospholipid bilayer and contain a variety of cargo, including proteins, nucleic acids (including DNA, mRNAs, miRNAs, and lncRNAs), lipids, and metabolites [11]. Their membrane proteins feature members of the tetraspanin family (CD63, CD9, and CD81), adhesion molecules like integrins, MHC class molecules, and various receptors [12]. The specific cellular origin of different EVs allows them to encapsulate diverse cellular components. Microvesicles primarily carry proteins linked to the plasma membrane and cytosol, reflecting their mode of formation. They also contain heat shock proteins and proteins undergoing post‐translational modifications. In contrast, apoptotic bodies include chromatin, nuclear‐associated proteins, some organelle proteins, and small amounts of glycosylated proteins [12] (Table 1). Table 1Physiochemical properties of the three main types of extracellular vesicles.TypesSizeBiogenesisMarkersPathwaysExosomes30–150 nmFusion of multivesicular bodies (MVBs) with the plasma membraneCD9, CD63, CD81, Alix, TSG101, Flotillin, Rab, and ESCRTESCRT machinery, syndecan‐syntenin‐ALIX complex, ceramide, tetraspanins, cytoskeletal elements, and arrestin domain‐containing protein 1 (ARRDC1)Microvesicles50–1000 nmOutward budding of plasma membraneIntegrins, selectins, CD40, Annexin A1, CK18, and MMP2ARF6 and other ARF family members, Rab, Rac1, and RhoA family members, ARRDC1Apoptotic bodies1–5 μm (1000–5000 nm) (sometimes up to 10 μm)Membrane blebbing and cellular fragmentation during apoptosisAnnexin V, phosphatidylserineRho‐associated coiled‐coil‐containing protein kinases 1 (ROCK1) and a caspase‐activated pannexin 1 channel (PANX1) Physiochemical properties of the three main types of extracellular vesicles. Biogenesis and Sorting of EVs The biogenesis and sorting of cargo molecules into EVs is regulated by a complex interplay of molecular mechanisms involving various sorting machinery and signaling pathways [5, 13]. Sorting machinery involved in EV biogenesis includes the endosomal sorting complex required for transport (ESCRT), the syndecan‐syntenin‐ALIX complex, tetraspanins, cytoskeletal elements, and arrestin domain‐containing protein 1. The ESCRT machinery is crucial for sorting ubiquitinated proteins into intraluminal vesicles within MVBs, which is essential for exosome formation [13, 14]. Tetraspanins participate in both MVB formation and the packaging of specific cargo into exosomes [15]. The sorting of cargo and shedding of microvesicles are closely linked to the regulation of cytoskeletal elements by several small GTPases, including ARF6, Rab, Rac1, and the RhoA family [16]. Arrestin domain‐containing protein 1 (ARRDC1) also plays a role in the shedding and release of microvesicles from the plasma membrane. Rho‐associated coiled‐coil‐containing protein kinases 1 (ROCK1) and the caspase‐activated pannexin 1 channel (PANX1) have been implicated in the formation of apoptotic bodies [17]. In addition to direct membrane budding during apoptosis, alternative pathways may exist for generating diverse subtypes and releasing apoptotic bodies following fusion with the plasma membrane and MVBs (Table 1). Dysregulation of vesicular sorting mechanisms impacts the cargo composition of specific types of EVs and their functional properties, which can contribute to disease development and progression. Tumor‐derived EVs frequently carry oncogenic proteins and microRNAs, such as EGFRvIII and miR‐1246, which contribute to increased cell proliferation, angiogenesis, and resistance to therapy [18, 19]. In neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, EVs mediate the intercellular transfer of misfolded proteins such as tau and α‐synuclein, exacerbating neuronal damage and accelerating disease progression [20, 21]. These pathogenic roles of EVs are discovered to be driven by abnormalities in their sorting machinery, involving the ESCRT complex and RNA‐binding proteins, which have emerged as promising targets for therapeutic intervention [22, 23, 24]. Understanding the unique characteristics of each EV type is crucial for studying the biological function and its application in diagnostics and therapeutics. Hence, current methods for isolating and characterizing EVs, their roles in physiological processes and disease development, their therapeutic potential, the challenges faced in clinical applications, and future research directions are presented. Methods for EV Isolation EVs share biophysical properties with supramolecular structures like lipoproteins and protein aggregates. Furthermore, the higher occurrence of these molecules in biological fluids often poses several challenges in the isolation and characterization of EVs. In serum and plasma, lipoproteins, such as HDL and LDL, contaminate EVs because of their similar size and density, affecting the purity of isolated EVs [3]. Tamm–Horsfall protein and albumin bind to EVs and form aggregates that interfere with quantitation [4, 5, 6]. Likewise, casein in milk forms micelles that share a similar size and density with EVs, making the isolation of milk‐derived EVs more intricate [7, 8]. To overcome such challenges, several strategies have been developed to isolate EVs of good purity and maximum yield. Isolation methods leverage distinct physical, biochemical, microfluidic, and immunological properties to separate EVs from extracellular proteins. Several methods exist for isolating EVs, each with distinct tradeoffs in yield, purity, and processing time. Ultracentrifugation, including differential, cushioned, and density gradient variants, separates EVs by density and is widely used but labor‐intensive, taking 4–8 h with low to medium yield. Size exclusion chromatography (SEC) offers a faster, gentler alternative (~20–30 min), with high yield and purity across all biofluids, though it cannot distinguish EV subtypes of similar size. Microfluidics‐based methods, such as dielectrophoresis, affinity isolation, and microfiltration, require minimal sample volumes and can be automated, but may need specialized reagents or frequent maintenance. Field‐flow fractionation (FFF), including asymmetric flow and electric variants, achieves high purity by separating particles using perpendicular force fields, though it demands specialized equipment. Finally, immunocapturing techniques, including microtiter plates, affinity columns, magnetic beads, and fluorescence‐activated cell sorting (FACS), deliver the highest purity by targeting specific surface markers with antibodies but consistently produce very low yields and are best suited for targeted rather than comprehensive EV isolation. Thus, methods for isolating EVs must be suitable, depending on the specific study and purpose. Key distinctions of these methods are summarized in (Table 2). Table 2Methods of extracellular vesicle Isolation.MethodSubtypesPrincipleYieldPurityProcessing times (approx.)Sample typesAdvantagesLimitationsReferencesUltracentrifugationDifferential ultracentrifugation (DUC)Multistep centrifugation based on density typically involves five centrifugation steps to separate EVs from cells, debris, and proteins.LowMedium4–6 hPlasma, serum, urine, cell culture mediaWidely used and considered reliable; Effective for isolating EVs from complex samples.Labor‐intensive and time‐consuming; Requires large sample volumes; Potential EV damage from high g‐forces; Inconsistent sedimentation due to biological variability and rotor differences.[25, 26]Cushioned ultracentrifugation (CUC)Utilizes a cushioning medium to protect EVs during centrifugation, enhancing separation based on density differences.MediumMedium5–7 hPlasma, serum, cell culture mediaBetter maintains EV integrity compared to DUC; Improved separation from proteins.Increased workload and cost; Still labor‐intensive.[27]Density gradient ultracentrifugation (DGC)Employs a density gradient medium (e.g., sucrose, iodixanol) to separate EVs based on their buoyant density during centrifugation.MediumVery high6–8 hPlasma, serum, CSF, cell culture mediaAllows isolation of distinct EV subtypes; Enhanced purity and preservation of EV integrity.Higher workload and expenses; Requires specialized gradient media; Time‐consuming.[25]Size exclusion chromatography (SEC)qEV columns (Gen 2)Separates particles based on size using a chromatography column filled with porous beads (e.g., Sepharose, Sephacryl).HighHigh20–30 minAll biofluids (small volumes)Gentle separation preserving EV integrity; Can be automated and scaled up; Higher purity and yield compared to ultracentrifugation; Quick processing time (approx. 20 min).Cannot distinguish between EV subtypes of similar sizes; Requires specific resins and columns; Possible co‐elution of similarly sized lipoproteins and protein complexes; Dilution of samples due to mobile phase.[28, 29]Microfluidics‐based methodsDielectrophoresis (DEP)Manipulates small fluid volumes on a microscale using devices that can separate EVs based on electrical properties.HighHigh10–30 minAll biofluids (small volumes)Requires minimal sample volumes (as low as 10 µL); Can be automated for high throughput.Frequent need for de‐clogging filters and channels.[30]Affinity IsolationAntibody‐based capture on microchannels.MediumVery high1–2 hPlasma, serum (small volumes)High recovery rates (ex‐ExoChip achieves > 90% for tetraspanins).Requires specialized reagents (e.g., antibodies for affinity methods).[31]Microfluidic FiltrationSize‐based filtration through microchannels.MediumMedium15–45 minPlasma, urine, cell culture mediaIt's simple, easy to scale, and cost‐effective.EV loss through adhesion and limited size resolution.[32]Field‐flow fractionation (FFF)Asymmetric flow FFF (AF4)Separates particles using a perpendicular force field or gradient in combination with a longitudinal flow within a semi‐permeable membrane channel.HighHigh1–2 hPlasma, serum, conditioned mediaEffective separation is based on specific properties like electrophoretic mobility.Requires specialized equipment and expertise; Not easily implemented with standard lab instruments.[33]Electric FFFElectric field‐based separationMediumHigh1‐3 hPlasma, serum, conditioned mediaCan isolate distinct EV populations.Necessitates sample pre‐concentration; Cannot be used as a standalone method and needs complex setup[34]ImmunocapturingMicrotiter plate‐based methodsUtilizes antibodies specific to EV surface protein markers to capture and isolate EVs from a mixture(e.g., Enzyme‐linked Immunosorbent Assay).Very lowHigh30–60 minPlasma, serum (small volumes)Produces highest purity EV samples.Lower overall yield compared to size or density‐based methods.[35]Affinity columnsColumn‐bound antibodies are usedVery lowVery high1–2 hPlasma, serumEffective for isolating specific EV subpopulations based on surface markers.Cannot capture all EVs due to reliance on specific markers.[35]Magnetic beadsAntibody‐coated magnetic beads are usedVery lowVery high1–3 hPlasma, serum, cell culture mediaProduces highest purity for specific EV populations; High recovery efficiency.Dependent on antibody specificity and availability.[36]Fluorescence‐activated cell sorting (FACS)Utilizes specific dyes or antibodies that bind to specific molecules on/in the cells, and the cells are sorted based on the emitted fluorescenceVery lowVery high2–4 hPlasma, serum (small volumes)Can sort based on multiple markers simultaneously.Typically used for targeted studies rather than comprehensive EV isolation; Very low yield and time‐consuming.[36, 37] Methods of extracellular vesicle Isolation. EVs are characterized by examining their size, structure, and molecular content to validate their identity and ensure sample quality [38] (Table 3). To evaluate size and concentration, common methods such as dynamic light scattering (DLS) or nanoparticle tracking analysis (NTA) are used, while transmission electron microscopy (TEM) offers fine‐grained pictures of EV morphology [9]. To confirm EV‐specific proteins, protein markers such as CD9, CD63, and CD81 are identified by mass spectrometry, flow cytometry, or western blotting [11]. Furthermore, EV cargo, including lipids and RNA, is investigated via lipidomics and nucleic acid analysis, which give insight into their functional roles [12]. Characterization guarantees that research and applications based on EVs are reliable. Table 3Standardized criteria for EV characterization.Characterization techniqueParameters measuredSample requirementsDetection range (approx.)AdvantagesLimitationsMISEV2018 recommendationReferencesNanoparticle tracking analysis (NTA)Size distribution, concentration108–109 particles/mL50–1000 nmSingle particle resolution, rapid analysisCannot distinguish EVs from other particlesPopulation analysis[39, 40, 41]Transmission electron microscopy (TEM)Morphology, size, structureSmall volume and fixed samples1–1000 nmHigh resolution, morphological detailSample artifacts, time‐consumingMorphology confirmation[25, 41, 42]Western blottingSpecific protein markers10–50 μg proteinAll protein sizesQuantitative, specific markersRequires prior knowledge of markersMarker validation[41, 43, 44]Flow cytometry (high‐sensitivity)Surface markers, heterogeneity106–107 particles/mL100–1000 nmSingle vesicle analysis, multiplexingSize limitations require fluorescent labelingSingle EV analysis[41, 45, 46]Dynamic light scattering (DLS)Hydrodynamic size, polydispersityHigh concentration required1–6000 nmRapid, nondestructiveBiased toward larger particlesSize verification[41, 47]Resistive pulse sensing (RPS)Size, concentration106–108 particles/mL40–10,000 nmSingle particle counting, tunable poresPore clogging, limited throughputAccurate counting[29, 41, 48]Atomic force microscopy (AFM)Surface topology, mechanical propertiesImmobilized samples1–1000 nmHigh resolution, mechanical propertiesSample preparation artifactsSurface analysis[41, 49, 50]Cryo‐electron microscopyNative structure, morphologyFresh and unfixed samples1–1000 nmNative state preservationExpensive, specialized expertise requiredNative morphology[41, 51, 52] Standardized criteria for EV characterization. Physiological Functions of EVs EVs in biological fluids play key roles in both physiology and pathology. By initiating signaling cascades, EVs influence gene expression and contribute to physiological functions such as immunomodulation, regeneration, and development [13]. Immunomodulation Immune cell‐derived EVs modulate the activity of the complement system [14] (Figure 2). While antigen‐presenting cell‐derived EVs inhibit membrane attack complex formation and mononuclear cell‐derived EVs scavenge complement components to prevent complement factors from acting on host cells [15, 16], C‐reactive protein‐bound EVs and T‐cell‐derived EVs activate the C1q pathway [17] and other complement components by phosphorylating complement factor 9 [53]. EVs derived from immune cells play a critical role in modulating the immune responses of neighboring immune cells via cell–cell interactions [54]. Dendritic cell‐derived EVs facilitate antigen presentation, T‐cell activation, and inflammation [55, 56]. Natural killer (NK) cell‐derived EVs exhibit pro‐apoptotic and cytotoxic effects on cancer cells, thus enhancing cancer surveillance and promoting NK cell proliferation [57]. Neutrophil‐derived EVs display both pro‐ and anti‐inflammatory properties, depending on the immune environment [58, 59]. EVs from T cells, including CD4+ helper, CD8+ cytotoxic, and T‐regulatory (Treg) cells, play immunomodulatory, cytotoxicity of pathogen‐infected cells, cancer cells and immune‐regulatory functions, respectively. While cytotoxic T‐cell‐derived EVs target non‐self‐peptides, Treg cell‐derived EVs inhibit immune responses [60, 61]. B cell‐derived EVs suppress immune responses by regulating T cells and NK cell activity. Together with T cells, B cell‐derived EVs function as suppressors or promoters of tumor [62]. Macrophage‐derived EVs are influenced by signals from other immune cells. Macrophage‐derived EVs have been shown to play a dual role, as pro‐inflammatory mediators in inflammatory diseases, fibrosis, and cancers, and as mediators of immunoregulation, anti‐tumor, pathogen clearance, and tissue repair [63] (Table 4). Cellular functions of extracellular vesicles (EVs). (A) Immunomodulatory role of EVs. Immune cell‐derived EVs exhibit diverse properties such as pro‐inflammatory, pro‐apoptotic, cancer surveillance, and immune cell proliferation. (B) Role of EVs in cell signaling. Mesenchymal stem cell‐ and macrophage‐derived EVs have pro‐ and anti‐apoptotic properties by modulating the cell signaling cascade. (C) Role in extracellular matrix remodeling and tissue regeneration. Mesenchymal stem cell‐ and cardiomyocyte‐derived EVs activate Wnt/catenin Akt pathways and differentiation of fibroblasts into myofibroblasts, thus enhancing wound healing and collagen deposition. Table 4The mechanistic role of EVs in immunomodulation, tissue remodeling, and regeneration.ConditionMechanistic effectsReferencesImmunomodulationComplement system(A) CD55 accelerates decay of C3 and C5 convertase, preventing complement activation on host cells. (B) CD59 prevents the formation of the membrane attack complex. (C) Complement receptor‐1 (CR1) scavenges complement components from circulation. (D) C‐reactive protein activates C1q of the complement pathway. (E) Casein Kinase 2 Phosphorylates C9, initiating the complement‐mediated pathway. [16] [64] [65] Dendritic cells (DCs) (A) DCs secreted exosomes activate T‐cells by leukocyte function antigen‐1 and ICAM2 signaling pathway. (B) DC‐derived EVs in C57/BL/6 mice induce inflammation in the spleen by the upregulation of the CCR7 chemokine receptor. [56, 66]Natural killer (NK) cellsNK cell‐derived exosomes express FasL that regulates the homeostasis of lymphocytes.[67]NeutrophilsNeutrophil‐derived EVs contain miR‐451a and miR‐150 that exert anti‐inflammatory roles at the inflammation sites.[60]T cellsT‐cell‐derived EVs constitute FasL and APO ligands promoting pro‐apoptotic properties and activating resting CD4+ cells.[68]T cellsT regulatory cells express miRNA containing exosomes that suppress Th1 cell proliferation and secretion of cytokines.[62]B cellsB‐cell‐derived EVs contain high levels of MHC‐II and FasL, which induce apoptosis of helper T cells; B‐cell‐derived EVs contain CD19+ and high levels of CD39 and CD73 that inhibit the cytotoxic function of CD8+ T cells.[69]MacrophageLncRNAs in macrophages modulate M2 macrophages and lncRNA AFAP1‐AS1 to promote tumor invasion and metastasis.[70]Regenerative and tissue repairCell deathIn lung injury, monocyte‐derived EVs transport caspase‐1 and casdermin D to vascular endothelial cells of the lungs and stimulate apoptosis; In sepsis, platelet‐derived EVs contain nitric oxide that stimulates caspase‐3 and promotes apoptosis of endothelial cells. [71] [72] Cell survivalIn spinal cord injury, MSC‐derived EVs enhance functional recovery by upregulating the expression of BCL‐2 and inhibiting the expression of Bax; In myocardial infarction, miRNA‐146a downregulates TNF and IL‐1 receptor‐associated kinase to promote recovery.[73]Tissue remodelingFibrosis reversalHuman adipocyte stem‐cell‐derived EVs prevent excessive fibrosis by elevating the ratio of collagen III and TGFβ‐3, which inhibits myofibroblast activity.[74]Fibrosis activationEVs derived from hypoxic tubular cells are enriched in miR‐150‐5p target SOCS1 gene, causing fibroblast activation and upregulating fibronectin expression, which aggravates renal fibrosis.[75]Fibrosis activationCardiomyocyte‐derived EV contains miR‐208a that promotes the differentiation of fibroblasts into collagen‐secreting myofibroblasts in cardiac tissue.[76]Tissue regenerationStem cell‐derived EVs stimulate the proliferation and migration of fibroblasts by activating WNT/β‐catenin and Akt signaling pathways.[77]Tissue regenerationStem cell‐derived EVs stimulate MMPs and phosphorylation of YAP to avoid excessive proliferation of fibroblasts and collagen deposition.[78]Tissue regenerationHepatocyte‐derived EVs contain ceramide, neutral ceramidase, and sphingosine kinase‐2 to initiate intracellular sphingosine‐1‐phosphate production that promotes hepatocyte proliferation and liver regeneration.[79] The mechanistic role of EVs in immunomodulation, tissue remodeling, and regeneration. [16] [64] [65] (A) DCs secreted exosomes activate T‐cells by leukocyte function antigen‐1 and ICAM2 signaling pathway. (B) DC‐derived EVs in C57/BL/6 mice induce inflammation in the spleen by the upregulation of the CCR7 chemokine receptor. [71] [72] Regeneration Tissue regeneration and repair vary across organisms and depend on stem cells' ability to migrate, differentiate, and repopulate damaged tissue. Key mechanisms include apoptosis, inflammation, immune surveillance, matrix remodeling, and cell proliferation [80]. EVs from mesenchymal stem cells (MSCs) play a crucial role by delivering growth factors, miRNAs, and mRNA, enhancing cell survival, regulating apoptosis, and promoting tissue regeneration [81]. EVs exhibit both pro‐ and anti‐apoptotic functions during tissue damage. In acute lung injury, monocyte‐derived EVs deliver caspase‐1 and gasdermin D to lung endothelial cells, promoting apoptosis [82]. In sepsis, platelet‐derived EVs release nitric oxide, activating caspase‐3 and inducing endothelial cell apoptosis [71]. In liver injury, hepatocyte‐derived EVs trigger caspases‐3 and ‐8, along with receptor‐interacting proteins, leading to both apoptosis and necroptosis [72]. In contrast, during acute kidney injury, EVs containing miRNAs (miRNA‐486‐5p and miRNA‐21) promote cell survival by targeting the tumor suppressor PTEN (phosphatase and TENsin homolog deleted on chromosome 10) and enhancing the proliferative response in tubular epithelial cells through CD44‐β–integrin interaction [83, 84]. In spinal cord injury, MSC‐derived EVs improve recovery by increasing anti‐apoptotic proteins (e.g., BCL‐2) and decreasing pro‐apoptotic proteins (e.g., Bax) [85]. Similarly, in myocardial infarction, cardio‐sphere‐derived EVs support cardiomyocyte recovery and prevent tissue necrosis, with miRNA‐146a playing a key role in downregulating inflammation [73]. Neutrophil and macrophage‐derived EVs contain NADPH oxidases, Akt signaling activators, Wnt, and myeloperoxidase, promote neurite growth, intestinal stem cell survival, wound healing, and tissue repair and regeneration [86, 87, 88]. Overall, EVs modulate apoptotic pathways to prevent tissue damage and improve functional outcomes during injuries. The extracellular matrix (ECM) is composed of collagen, fibronectin, elastin, proteoglycans, and matrix metalloproteinases, providing structural support to tissues. During tissue regeneration, immune cells, fibroblasts, and myofibroblasts actively remodel the ECM. EVs derived from these cells influence ECM remodeling, healing, and scar tissue formation [89]. EVs from human adipocyte stem cells help prevent fibrosis by inhibiting myofibroblast activity and collagen deposition, promoting a favorable collagen‐III to collagen‐I ratio and a TGFβ‐3 to TGFβ‐1 ratio [90]. miRNA‐30a, found in lung spheroid cell‐derived EVs, improves lung fibrosis [74]. In ischemia–reperfusion (I/R) injury, EVs from tubular epithelial cells reduce fibronectin and renal fibrosis, while EVs from hypoxic tubular cells, enriched in miR‐150‐5p, activate fibroblasts, exacerbating fibrosis [91]. Cardiomyocyte‐derived EVs containing miR‐208a promote fibroblast differentiation into collagen‐producing myofibroblasts; blocking miR‐208a reduces fibrosis post‐infarction [75]. Thus, EVs can both support and hinder ECM remodeling during regeneration. Targeting pro‐ and anti‐fibrotic EVs could offer strategies to optimize ECM remodeling, reduce scarring, and enhance tissue regeneration in clinical settings (Table 4). Stem cell‐derived EVs activate resident cells, promoting their proliferation and differentiation. MSC‐EVs enhance wound healing by stimulating fibroblasts, epidermal cells, and endothelial cells. MSC‐EVs activate the WNT/β‐catenin and Akt pathways to inhibit apoptosis and accelerate healing while regulating scar tissue formation by stimulating matrix metalloproteinases [76] and preventing excessive fibroblast proliferation through YAP phosphorylation [92]. Amniotic fluid stem cell‐derived EVs promote intestinal epithelium regeneration via Wnt signaling [78]. MSC‐EVs and induced pluripotent stem cell‐derived EVs improve cardiac regeneration and function in ischemic heart disease models. Embryonic stem cell‐derived EVs, containing vascular endothelial growth factor (VEGF), activate the PI3K/Akt pathway in endothelial cells, promoting angiogenesis [93]. miRNA‐21 enhances angiogenesis by targeting PTEN, activating Akt/ERK1/2 pathways, and increasing VEGF and HIF‐1α expression [94]. In the brain, MSC‐derived miRNA‐133b supports axonal growth while preventing astrocyte proliferation [95]. In the liver, MSC‐EVs containing lncRNA H19 and miRNA‐17 exhibit anti‐inflammatory and anti‐fibrotic effects, helping reverse fibrosis, stimulate antioxidants, and promote regeneration [96]. Hepatocyte‐derived EVs containing ceramide stimulate sphingosine‐1‐phosphate production, enhancing hepatocyte proliferation and liver regeneration after injury [97]. These examples showcase the tissue repair, proliferation, and regenerative prowess of EVs across multiple organs. EVs in Disease Pathogenesis Cancer Cancer cells produce EVs, a specialized form of cell communication that contributes to the tumor microenvironment (TME), promotes cancer cell growth and survival, and enhances invasive and metastatic activities [79, 98]. EV secretion is generally higher in malignant cells than in non‐malignant cells, likely due to calcium mobilization from the endoplasmic reticulum and activation of ADP‐ribosylation factor 6 (ARF6) [99]. RhoA [100] regulation of p53 [101], and other oncogenes. Oncogenes such as MYC, RAS, and AURKB have been shown to modulate EV content by enriching them with specific miRNAs (e.g., miR‐21 and miR‐1246), proteins (e.g., integrins and annexins), and long non‐coding RNAs that promote epithelial‐to‐mesenchymal transition (EMT), angiogenesis, and immune evasion [102]. For example, HRASG12V‐transformed cells produce EVs carrying pro‐metastatic miRNAs and altered surface integrins (e.g., integrin αvβ5), which direct EVs to the liver, promoting pre‐metastatic niche formation [102]. Likewise, MYC‐overexpressing cancer cells secrete EVs enriched in miR‐155 and miR‐210, which facilitate angiogenesis and metabolic reprogramming in recipient endothelial and stromal cells [103]. Mechanistically, these oncogenic EVs interact with target cells via receptor‐mediated endocytosis or membrane fusion, delivering their cargo to reprogram gene expression and activate signaling pathways such as PI3K/AKT, MAPK, and TGF‐β, all of which are associated with enhanced invasion and metastasis [102, 104, 105]. Recent studies have emphasized the significant role of EVs in regulating cell signaling across various cancers, including hepatocellular carcinoma (HCC) [106, 107, 108], breast cancer [109], prostate cancer [110, 111], and non‐small cell lung cancer [112]. Hence, EVs play a crucial role in cancer progression by facilitating tumor‐supportive cell signaling, enhancing metastatic potential, and promoting resistance mechanisms against chemotherapy. Angiogenesis EVs play an important role in tumor angiogenesis by transporting bioactive molecules such as proteins, lipids, and miRNAs that modulate the TME [113, 114]. Studies have shown that EVs promote endothelial cell proliferation, migration, and tube formation, which are the essential steps in new blood vessel formation [115, 116, 117, 118]. EVs carry angiogenesis‐related miRNAs, such as miR‐21, miR‐155, miR‐210, and miR‐296 [94, 119, 120, 121, 122], lysyl oxidase homolog 4 [123], lncRNA‐H19, and circRNA‐100338 [124, 125], which regulate the expression of pro‐angiogenic factors like VEGF and hypoxia‐inducible factor‐1α (HIF‐1α). Under hypoxic conditions, EVs transfer HIF‐1α to surrounding cells to intensify angiogenesis [126, 127]. Also, tumor‐derived small EVs carry EGF receptors, which are transferred to HUVECs to stimulate VEGF production and blood vessel formation [128, 129, 130]. Furthermore, EVs carry enzymes like matrix metalloproteinases that degrade the ECM, facilitating endothelial cell invasion and sprouting [131]. Hence, understanding the role of EVs in angiogenesis may reveal therapeutic targets to inhibit cancer progression [126]. Neurodegenerative Disorders EVs play a complex role in the pathogenesis and potential treatment of neurodegenerative disorders [132, 133]. EVs facilitate the spread of misfolded proteins, such as amyloid‐beta, tau, and alpha‐synuclein, contributing to disease progression in Parkinson's disease [134], Alzheimer's disease [135, 136], and other neurodegenerative disorders, including amyotrophic lateral sclerosis [137, 138]. Pro‐inflammatory cytokines, such as IL‐1β and TNF‐α, are carried by EVs generated by activated microglia and astrocytes, aggravating neuroinflammation [139, 140]. Additionally, EVs transport miRNAs and long non‐coding RNAs that regulate gene expression, potentially influencing pathological or protective processes in neurodegenerative diseases [141]. Interestingly, neuroprotective substances, such as brain‐derived neurotrophic factor, can be delivered via EVs derived from stem cells or engineered for therapeutic purposes, showing promise for the regeneration of damaged neural tissues [142, 143]. Cardiovascular Diseases EVs play a critical role in both physiological and pathological conditions within the cardiovascular system [144]. Cardiovascular EVs facilitate extracellular signaling in both healthy and diseased states, including in vascular pathologies such as atherosclerosis, coronary heart disease, stroke, and peripheral arterial disease [145, 146]. Increasing evidence suggests that the effects of EVs on target cells are primarily dependent on the miRNAs and proteins they transfer, particularly the high expression of miR‐217, miR‐208a, and miR‐27 b‐3p found in pathological conditions [147]. Additionally, EVs from various sources can exert cardioprotective effects in conditions such as myocardial infarction [148], hindlimb ischemia, and stroke by reducing platelet aggregation and inhibiting CD36 expression through ubiquitination, thereby preventing atherosclerotic thrombosis [149, 150]. Infectious Diseases EVs play a critical role in the pathogenesis and progression of various infectious diseases by mediating intercellular communication and influencing host‐pathogen interactions [151]. EVs can carry viral RNA, proteins, and miRNAs, facilitating immune evasion and viral replication. They also modulate immune responses by affecting T cells and macrophages. Recent studies have shown that EVs are critical to the onset of viral illnesses, including HIV, SARS‐CoV‐2 (COVID‐19), hepatitis B, and hepatitis C [151, 152, 153]. It is well recognized that EVs from eukaryotic cells play a significant role in bacterial infections by influencing both the progression of the infection and the healing timeline [154, 155, 156]. EVs transport fungal antigens and enzymes like aspartyl proteases, which contribute to biofilm formation and immune modulation, leading to severe infections [157]. Autoimmune Disorders EVs from antigen‐presenting cells such as dendritic cells and macrophages can carry autoantigens, promoting the activation of autoreactive T and B cells, which trigger immune responses in autoimmune disorders like rheumatoid arthritis and systemic lupus erythematosus [158, 159]. EVs with surface antigens can bind to ECM proteins or circulating immunoglobulins, aiding the immune system in recognizing perceived threats, with these responses being mediated by the complement system [160]. Studies have shown that EVs from activated immune cells or damaged tissues carry inflammatory mediators and cytokines, amplifying immune responses in diseases like multiple sclerosis and type 1 diabetes [161, 162, 163, 164]. In conclusion, EVs are key mediators in diverse pathological processes, including cancer, autoimmune, infectious, and cardiovascular diseases (Figure 3). Deeper insights into EV–disease interactions offer promising avenues for developing diagnostic biomarkers and targeted therapies. Such advances support precision medicine, ultimately improving patient care and outcomes. The schematic presentation illustrates extracellular vesicles' therapeutic potential in infectious diseases, neurological disorders, immunology, cardiovascular diseases, and cancer. AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; CRP, C‐reactive protein; PD, Parkinson's disease. Applications of EVs Drug Delivery Vehicle The effectiveness of drug delivery systems largely depends on the characteristics of the delivery vehicle [165, 166, 167]. While liposomes are the best‐established synthetic nanocarrier platform and therefore serve as a common benchmark for comparison, other engineered delivery systems, such as polymeric nanoparticles, dendrimers, and lipid–polymer hybrid nanoparticles, have also been explored for drug delivery applications. In contrast, EVs are gaining increasing attention due to their endogenous origin, inherent biocompatibility, and natural targeting capabilities (Table 5). These differences highlight the unique biological advantages of EVs compared with conventional synthetic nanocarriers. EVs naturally carry proteins, lipids, and nucleic acids and can traverse biological barriers [168]. Molecules like CD47 help them evade immune clearance, while integrins influence organ‐specific targeting [169, 170]. For example, integrin α6β4 and α6β1 promote lung targeting, whereas αvβ5 promotes liver accumulation [169]. Table 5Key differences between extracellular vesicles and liposomes as biological and synthetic nanocarriers for drug delivery.FeatureExtracellular vesiclesLiposomesOriginNaturally secreted vesicles derived from cellsArtificial vesicles composed of synthetic phospholipidsMembrane structurePhospholipid bilayers contain proteins, lipids, and nucleic acidsThe phospholipid bilayer is typically composed of synthetic lipid mixturesTargeting capabilityIntrinsic targeting mediated by membrane proteins (e.g., integrins and tetraspanins)Targeting requires surface modification (e.g., ligands, antibodies, and PEGylation)Immune recognitionGenerally lower immunogenicity due to endogenous originSome formulations may trigger complement activation or rapid clearance by the reticuloendothelial systemAbility to cross biological barriersCan naturally cross certain biological barriers, such as the blood–brain barrierLimited intrinsic barrier penetration; often requires ligand modificationCargo loadingLimited loading capacity: cargo loading methods include electroporation, incubation, and sonicationHigher loading capacity for both hydrophilic and hydrophobic drugsCompositionComplex composition including proteins, lipids, and nucleic acids from parent cellsDefined synthetic lipid compositionManufacturingIsolated from biological sources, scalability remains challengingScalable and well‐established manufacturing processesClinical maturityEmerging therapeutic platformSeveral clinically approved liposomal formulations Key differences between extracellular vesicles and liposomes as biological and synthetic nanocarriers for drug delivery. Naturally derived EVs, such as those from MSCs or bovine colostrum, inherently carry bioactive molecules and exhibit therapeutic properties without further modification. In contrast, engineered EVs are modified post‐isolation or via donor cell manipulation to enhance targeting, cargo loading, or therapeutic efficacy. These modifications can include surface functionalization with ligands or incorporation of therapeutic agents, distinguishing them from their natural counterparts [171]. These traits make EVs attractive for delivery, offering longer circulation times, low cytotoxicity, and blood‐brain barrier penetration [171]. Their non‐replicative, nonmutagenic nature offers safety advantages over cell therapies [172]. EVs are being tested as nonviral vectors in gene therapy for neurological, oncologic, and cardiovascular diseases [172, 173, 174]. Therapeutic Applications and Emerging Strategies EVs have been studied in various gene delivery applications, including pDNAs, siRNAs, mRNAs, antisense oligonucleotides, circRNAs, and CRISPR/Cas9 [175] (Figure 3). Their nanoscale size and flotation density (1.1–1.18 g/mL) favor delivery across barriers like the BBB [176]. Exosomes, a subtype of EVs, show regenerative and immunomodulatory effects. In the nervous system, they support myelin formation, axonal repair, and neuron survival [177, 178]. Exosomes also carry immunologically active cargo. Regulatory T cell‐derived EVs transport anti‐inflammatory miRNAs (miR‐146a‐5p, miR‐150‐5p, and let‐7d) that suppress pro‐inflammatory cytokines [61, 179, 180], modulating immune responses in autoimmunity and cancer. In cancer, tumor‐derived EVs can propagate metastasis and therapy resistance by transferring oncogenic factors. Hoshino et al. linked tumor‐derived EV integrins to organotropic metastasis [170], stressing the need for rigorous purification to eliminate pro‐tumorigenic contaminants. In neurodegeneration, EVs can either spread misfolded proteins (tau, α‐synuclein, and Aβ) or deliver neuroprotective cargo from MSCs and neural stem cells [181, 182, 183]. Bioengineered EVs expand therapeutic flexibility. For instance, RVG‐ or GE11‐tagged EVs target brain and EGFR+ tumors via fusion to Lamp2b or CD63 scaffolds [184, 185]. These modifications enhance EV targeting precision and therapeutic efficacy. Similarly, αv‐integrin‐enriched EVs improve lung fibrosis and tumor vasculature targeting [169, 186, 187]. Hybrid EV‐liposome systems combine EV targeting with liposome drug‐loading efficiency. PEG‐mediated fusion enables the co‐delivery of membrane‐bound and soluble drugs while preserving EV membrane proteins [188]. Naturally derived EVs (e.g., from bovine colostrum) are also promising. These vesicles exhibit anti‐inflammatory and antioxidant properties, with good scalability and safety profiles [189, 190]. Several methods are used for therapeutic loading: passive incubation, electroporation, sonication, freeze‐thaw, and extrusion [191]. Electroporation uses electric fields to permeabilize membranes, but it may cause cargo aggregation [192]. Electroporation uses electric fields to permeabilize membranes but may cause cargo aggregation. Sonication aids loading but risks vesicle damage [192]. Optimization is critical to balance efficiency and EV integrity. Clinical translation requires scalable, reproducible loading methods, coupled with quality control, to manage batch variation and confirm biological activity. These aspects are crucial for clinical trials (Table 6). Table 6Extracellular vesicle‐based therapeutics in clinical trial.ConditionNumber of subjectsAge (years)PhaseRecruiting statusNCT numberIschemic stroke6918–75Phase 1Not yet recruitingNCT06612710Non‐ischemic dilated cardiomyopathies1218–80Phase 1RecruitingNCT05774509Neurodegenerative diseases10040–80Phase1Not yet recruitingNCT06607900Acute respiratory distress syndrome8118–85Phase 1/2Not yet recruitingNCT05127122Diabetic foot ulcers40> 18Phase 2RecruitingNCT06319287Acute myocardial infarction60> 18Phase 4CompletedNCT02931045Non‐small cell lung cancer25> 19Phase 2CompletedNCT03228277Lung adenocarcinoma40> 19Phase 2RecruitingNCT05469022Chronic post‐COVID‐19 syndrome6018–85Phase 1/2Not yet recruitingNCT05116761Covid‐19 acute respiratory distress syndrome15> 18Phase 1/2Not yet recruitingNCT06002841Bronchopulmonary dysplasia265Birth–10 daysPhase 1/2RecruitingNCT06279741Acute respiratory distress syndrome97018–75Phase 3RecruitingNCT05354141COVID‐1924018–75Early Phase 1RecruitingNCT05787288Chronic cough after COVID‐19 infection8018–80Early Phase 1RecruitingNCT05808400Premature ovarian failure1020–38 (only females)Phase 1/2RecruitingNCT06202547Crohn's disease1018–75Phase 1Active, not recruitingNCT05130983Ulcerative colitis1018–75Phase 1Active, not recruitingNCT05176366Retinitis pigmentosa15> 18Phase 1/2RecruitingNCT06242379Perianal fistulizing Crohn's disease3618–75Phase 1/2Active, not recruitingNCT05836883Cochlear implant surgery‐related trauma11> 18Phase 1/2Not yet recruitingNCT06545175Chronic otitis media100NAPhase 2/3UnknownNCT04761562Non‐ischemic dilated cardiomyopathies1218–80Phase 1RecruitingNCT05774509Acute myocardial infarction60> 18Phase 4CompletedNCT02931045Neuromyelitis optica spectrum disorders6918–65Phase 1Not yet recruitingNCT06620809Amyotrophic lateral sclerosis3818–80Phase 1/2RecruitingNCT06598202 Extracellular vesicle‐based therapeutics in clinical trial. Challenges and Perspectives Key translational hurdles remain. Immunogenicity is a concern, especially with repeated or non‐autologous administration [193]. Macrophage‐mediated clearance of EVs has been observed due to recognition of surface proteins and opsonins [194]. Mitigation strategies include expressing CD47 (“don't eat me” signal) or using autologous sources [195]. Immune toxicities like cytokine storms must be preclinically evaluated [196, 197]. Another challenge is the oncogenic risk of TDEVs, which transfer malignant factors and promote metastasis [169, 198]. Quality control and stringent purification are essential to eliminate these risks. Scalability and standardization are major bottlenecks. Natural EV yields are low, and isolation techniques like ultracentrifugation are laborious. Solutions include high‐density bioreactors, EV‐mimetic nanovesicles, and scalable filtration systems [199], though GMP‐compliant workflows are still evolving. Formulation and storage stability add complexity. Artificial EVs or EV mimics are being explored to overcome these barriers [188]. Hybrid EV‐liposome fusions offer modularity but require compatible materials. Blocking tumor EV secretion via ESCRT and tetraspanin pathways is also under study [200], though compensatory mechanisms complicate outcomes [201]. EVs have emerged as promising sources of diagnostic and prognostic biomarkers due to their ability to carry disease‐specific nucleic acids, proteins, and lipids that reflect the physiological state of their cells of origin. EV‐associated biomarkers have been identified using a variety of analytical techniques, including quantitative PCR, RNA sequencing, proteomic analysis, and high‐sensitivity flow cytometry. These approaches enable the detection of EV‐derived molecular signatures with potential diagnostic and prognostic value across multiple diseases. Representative examples of EV‐based biomarkers reported across different pathological conditions are summarized in Table 7. Table 7Extracellular vesicles as biomarkers in pathology.ConditionEV biomarkersDetection methodsExperimental modelsPhenotypic effectsReferencesCancerHepatocellular carcinoma (HCC)CAFs/miR‐1228‐3p/EVsEV isolation followed by RT‐qPCR and Western blottingIn vitro HCC9724 cell line; athymic BALB/c nude mouseThis leads to chemoresistance by activating the PI3K/AKT pathway[202]HCCmiR‐451/EVsRT‐qPCR analysis of EV‐derived miRNAIn vitro HepG2, Huh‐7, Hep3B, and SSMC‐772 cell linesmiR‐451a inhibits the proliferation, invasion, and migration, suggesting mIR‐451a is a novel target in HCC[203]HCCCAFs/circZFR/EVsqRT‐PCR and western blotIn vitro Huh7 and MHCC97L cell lines, athymic nude mousecircZFR to HCC cells inhibits the STAT3/NF‐KB pathway and promotes HCC development and chemoresistance[204]HCCBMM/miR‐338‐3PqRT‐PCR and western blotIn vitro Huh7 and MHCC97L cell linesBMSC‐derived exosome miR‐338‐3p delays HCC by down‐regulating EST1, providing a new promising treatment target for HCC[205]Prostate cancermiR‐424/EVsRT‐qPCR and miRNA expression analysisIn vitro LNCaP and RWPE‐1 cell lines; Transgenic and PDX mouseInduces tumorigenesis and stemness in normal epithelial cells[111]Lung adenocarcinomamiR‐23a/EVRT‐qPCR, TEM, and western blotIn vitro NCI‐H1437, H1648, H1792, and H2087 cell lines; BALB/c nude mouseAccumulation of HIF1α leads to angiogenesis and vascular permeability, promoting the migration of cancer cells[206]Non‐small cell lung cancerBMSC‐miR‐598/EVRT‐qPCRIn vitro H1299, A549, H522, and H460 cell lines; BALB/c nude mouseDecreases migration, invasion, and proliferation of small‐cell lung cancer[207]Colorectal cancerBMSC‐miR‐34a‐5p/EVRT‐qPCR and western blotXenograft BALB/c nude mouseDecreases tumorigenesis by downregulating myc/PTEN axis[208]Pancreatic cancerBMSC‐EVs/miR‐148a‐3p and engineered EVs (ITGA5‐EVs‐148a)EV isolation by ultracentrifuge followed by Western blotting and RT‐qPCR detectionIn vitro PANC‐1 cell line; BALB/c male nude miceITGA5‐EVs‐148a effectively suppressed the proliferation and migration of pancreatic CAFs by targeting ITGA5 through the TGF‐β/SMAD pathway[209]Pancreatic cancerBMSC‐EVs/miR‐338‐5pWestern blotting and RT‐qPCRIn vitro PANC‐1, MIA‐PaCa‐2 and CFPAC1 cell lines; BALB/c nude mouseDecreases migration, invasion, and tumor formation[210]Oral squamous cell carcinomaCAFs‐ miRNA‐382‐5p/EVsRT‐qPCRIn vitro CAL‐27 cell lineInduces metastatic potential[211]Cardiovascular diseasesMyocardial infarctionmiR‐129‐5p/EVsRT‐qPCR and western blotMyocardial infarction induced by coronary artery ligation in C57B/L6Myocardial infarction mice treated with exosomes overexpressing miR‐129‐5p enhance cardiac function, decrease inflammatory cytokines, and decrease expression of HMGB1.[212]Acute myocardial infarctionIslet‐MSC/EVWestern blottingAcute myocardial infarction induced by coronary artery ligation in C57B/L6Elevates angiogenesis and survival of endothelial cells[213]Ischemic heart diseaseMonocyte/MSC‐EVWestern blotting and RT‐qPCRMyocardial ischemia–reperfusion injury induced by coronary artery ligation in C57B/L6Elevates the endothelial maturation and cardiac function[214]Cardiac ischemia/reperfusionmiRNA‐29cRT‐qPCRIschemia induced in C57B/L6 mice by left anterior descending coronary artery ligationDecreases autophagy by downregulating PTEN/Akt/mTOR signaling[215]Myocardial infarctionBMSC‐miR‐29b‐3bpRT‐qPCR and TEM analysisMyocardial infarction induced by left anterior descending coronary artery ligation in SD ratIncreases myocardial angiogenesis[216]AtherosclerosismiR‐23a‐3p/EVRT‐qPCRCarotid atherosclerosis is stimulated by a high‐fat, high‐cholesterol diet and partial ligation in SD ratAccelerate atherogenesis in remote locations by promoting endothelial inflammation[217]FibrosisRenal interstitial fibrosisMicroRNA‐216a/EVRT‐qPCRIn vitro NRK‐52E cell line; CD‐1 mouseActivates PTEN/Akt pathway[218]Interstitial pulmonary fibrosislncRNA/EVsRT‐qPCR, RNA expression analysis, and western blotInterstitial pulmonary fibrosis induced by Bleomycin in C57B/L6Activates lung fibroblasts and induces IPF[219]Pulmonary fibrosisBMSC/EVsWestern blotting, RT‐qPCR, TEM, and NTA analysisBleomycin‐induced pulmonary fibrosis model in C57B/L6Shifts the proinflammatory monocytes to anti‐inflammatory monocytes[220]Neurodegenerative diseasesAlzheimer's diseaseMSC‐ microRNA‐29c‐3p/EVRT‐qPCR and western blotAlzheimer's disease model induced by injecting oligomer Aβ1–42 in SD ratInduces Wnt/β‐catenin pathway and ameliorates Alzheimer's disease[221]Cerebral ischemia–reperfusion injuryBMSC‐miR‐145TEM analysis and western blotBV2 microglial cells and mouse bone marrow MSCs; SD ratDownregulates FOXO1 expression and infarct area[222]Ischemic strokeBMSC‐EVsWestern blotting, TEM, and NTA analysisCerebral ischemia induced by middle cerebral artery occlusion in SD ratsElevates neurological function and micro‐vessel density[223]Brain ischemic injuryBMSC‐EV/miR‐132‐3pWestern blot and NTA analysisIschemic stroke induced by transient middle cerebral artery occlusion surgery in C57B/L6Decreases blood–brain barrier dysfunction and ROS production[224]Abbreviations: NTA, nanoparticle tract analysis; TEM, transmission electron microscopy. Extracellular vesicles as biomarkers in pathology. Abbreviations: NTA, nanoparticle tract analysis; TEM, transmission electron microscopy. With advances in EV engineering, hybrid designs, and biomanufacturing, EV‐based therapeutics may become next‐generation clinical tools if key issues in safety, standardization, and scalability are resolved. Conclusion In conclusion, EVs offer transformative potential in both understanding cellular communication and advancing therapeutic applications. Our paper highlights significant progress in EV research, demonstrating their promise as powerful biomarkers and novel therapeutic tools. Despite challenges related to EV isolation, characterization, and immune responses, ongoing innovations in isolation techniques, standardized characterization, and targeted drug‐delivery methods are paving the way for successful clinical application of EV‐based therapies. While EV‐based strategies offer exciting potential for advancing precision medicine, their clinical impact will depend on overcoming key challenges related to scalability, immunogenicity, and regulatory translation. Author Contributions Kajal Kamra: conceptualization, writing – original draft. Satya Kumar Lalam: methodology, project administration. Shefali Srivastava: investigation, visualization. Madan Kumar Arumugam: writing – review and editing, formal analysis. Lokesh Kumar Boopathy: conceptualization, writing – review and editing, writing – original draft, supervision. Simran Takkar: resources, data curation. Zhiqiu Xia: software, methodology. Sabarinath Peruvemba Subramanian: investigation, validation. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Transparency Statement Dr. Kajal Kamra affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. Contributor Information Kajal Kamra, Email: kajal.kamra@unmc.edu. Lokesh Kumar Boopathy, Email: simretupwork@gmail.com. Data Availability Statement Data sharing is not applicable to this article as no data sets were generated or analyzed during the current study. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no data sets were generated or analyzed during the current study.